N. Anthony Coles, Director at Cerevel Therapeutics Holdings, Inc. (CERE), sold 50,000 shares at $30.03 ($1.5M) on 2023-07-11, disclosed to the SEC on 2023-07-13.
Scheduled sale ($1.5M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CERE | SELL | 2024-05-14 | $2.1M | — | Filing → |
| CERE | SELL | 2024-04-03 | $2.1M | — | Filing → |
| CERE | SELL | 2024-03-06 | $2.1M | — | Filing → |